Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Leukemia|August 28, 2015
Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosisB M Solomon, K G Chaffee, J Moreira, et al.
Journal of Virology|November 13, 1998
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virusM Robert-Guroff, H Kaur, L J Patterson, et al.
Blood|April 18, 1998
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory GroupP R Greipp, T Leong, J M Bennett, et al.
Leukemia|June 22, 2001
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomyR Fonseca, M M Oken, D Harrington, et al.
British Journal of Haematology|February 15, 2002
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemiaD F Jelinek, R C Tschumper, S M Geyer, et al.
American Journal of Hematology|November 1, 1988
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working groupB D Cheson, J M Bennett, K R Rai, et al.
Leukemia|July 30, 2016
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcomeS Barrio, T D Shanafelt, J Ojha, et al.
Nature Medicine|December 1, 2001
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaquesI M Belyakov, Z Hel, B Kelsall, et al.
Leukemia|July 12, 2012
Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controlsJ Moreira, K G Rabe, J R Cerhan, et al.
Journal of Virology|December 12, 2001
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiencyR Pal, D Venzon, N L Letvin, et al.
Pageof 19